Hepatitis B Foundation
Institute for Hepatitis and Virus Research

2012 Annual Report

Excellent Science Rooted In Human Compassion
Dear Friends,

The Hepatitis B Foundation (HBF) continues to be the beacon of hope for those concerned about and affected by hepatitis B and liver cancer. After 20 years, we have become the nation’s leading nonprofit research and disease advocacy organization for hepatitis B.

Our twin goals of significantly increasing awareness about hepatitis B and of delivering new discoveries that help people with hepatitis B and liver cancer—within the next 3 years—is highly ambitious. But we are well on our way.

To achieve this, the HBF Board adopted a comprehensive strategic plan in 2012 that leverages its many partnerships. We are building on our research institute, the Institute for Hepatitis and Virus Research (IHVR); our academic partner, Drexel University College of Medicine; our biotech partner, the Pennsylvania Biotechnology Center that we created to incubate companies; our federal partners that include the Centers for Disease Control and Prevention, U.S. Office of Minority Health, National Institutes of Health; and our national nonprofit partners.

So, we are not going it alone. Partnerships are key to our success and future growth.

This annual report shows that 2012 has been one of our most productive years. For example, we have been at the forefront of creating the first Hep B United national campaign that has more than 15 community-based coalitions participating from across the country; and helping to protect HBV-infected healthcare workers and students from discrimination by urging the CDC to update its 1991 HBV recommendations.

We are not only making noise in outreach, however, but in discovery research as well. With our academic partner, we have discovered new ‘lead” compounds with promising activity against hepatitis B and liver cancer, as well as new ways for the early detection of liver cancer.

We have made great progress since our creation in 1991. Simply put, the Hepatitis B Foundation has found a way to get even closer to our goal of… making hepatitis B history!

With appreciation,

Timothy M. Block, Ph.D.  
President and Co-Founder

Joel D. Rosen, Esq.  
Chairman

Our Mission

The Hepatitis B Foundation is the nation’s leading nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide through research, education and patient advocacy.

RESEARCH HIGHLIGHTS

HBF/IHVR scientists work in teams with our academic partner, Drexel University College of Medicine, on biomarker and drug discovery and understanding the disease process.

I. Detect Liver Cancer Early

Hepatocellular carcinoma (HCC or primary liver cancer) and cirrhosis are the most serious consequences of chronic hepatitis infections. Detecting these diseases early, to allow for interventions to be used when the disease is most responsive, is considered to be one of the best ways to improve patient outcomes.

- **HCC and liver cirrhosis have a characteristic fucosylation profile**
  
  Our work has shown that people with HCC have elevated levels of fucosylated glycan (a sugar attached to proteins) in their circulation. This is important to know, since it will help in the design and use of new cancer detection markers, as well as in understanding more about the disease. (Mehta et al, 2012; Norton 2012; Liang et al, 2012)

- **Total serum glycan analysis is superior to lectin-ELISAs for the early detection of HCC**
  
  We have identified more than 30 glycoproteins that contain increased fucosylation with HCC and/or cirrhosis and have tracked their N-glycans in plate-based assays to detect HCC. (Communale et al, 2013)

- **New biomarker to detect AFP-negative liver cancers**
  
  We have found that increased levels of alpha (2,6) linked sialic acid on serum alpha-1-anti-chymotrypsin could be used for the early detection of HCC in patients who test negative for alpha fetoprotein. (Mehta et al, 2012)

- **Possible marker for Cholangiocarcinoma (CCC)**
  
  There is no effective blood test for CCC, or bile duct cancer. Not even AFP has any use. We have found that fucosylated Fetuin-A was promising as a marker of CCC. (Mehta et al, 2013)

- **Liver cancer DNA detected in the blood and urine can be both a disease and treatment marker**
  
  We have discovered that liver cancer cells methylate “proto-oncogenes” in a way that is distinct from healthy cells, and developed new assays to detect “cancer cell” derived DNA in the urine and blood of patients. (Lin et al, 2011, 2012; Jain et al, 2012; Song et al, 2012)

Innovation + Research
II. New Therapies for Chronic Hepatitis B and Liver Cancer

Treatment of chronic HBV infection is very different today than 20 years ago since there are now clear medical options. However, half of those eligible for treatment do not benefit from these drugs, so we are focused on helping these patients and looking for new ways to cure hepatitis B.

Of particular interest is inhibiting the HBV covalently closed circular DNA (cccDNA), thought to be the permanent fingerprint of the virus in the liver. Liver cancer treatments is a high priority for us as well.

• New cell-based assay for studying transcription regulation of cccDNA and discovery of several “hit” compounds. (Cuconati, in progress; Liu et al, 2013)
• Discovery that interferon-alpha inhibits hepatadna-virus transcription by epigenetic modification of cccDNA mini-chromosomes and methods to suppress cccDNA. (Chang 2012; Guo et al, 2012)
• Discovery that host cellular non-homologous end joining DNA repair pathway is essential for cccDNA formation from double-stranded linear DNA. (Guo H et al, 2012)
• Discovery of new inhibitors of HBV pregenomic RNA-nucleocapsid formation. (Campagna et al, 2013)
• Screening of our Natural Products Library for cccDNA inhibitors is ongoing.
• Discovery of novel broad-spectrum antivirals through selective modification on innate immune response. (Chang 2012; Guo et al, 2012)
• Discovery of a compound that is highly selective and toxic to HCC in cell culture and animals. (Cuconati et al, 2012)

III. Understanding the Disease Process

We have focused on understanding the molecular pathway of HBV covalently closed circular (ccc) DNA formation and viral egress (i.e. movement of virus within host cell). Our most current study showed that deproteinization of viral double-stranded linear DNA also took place in the cytoplasm. (Guo et al, 2012)

Our Natural Products Institute

In 2011, Merck & Co. gave us their entire U.S. collection of natural products. As much as 50% of all medicines in use today came from natural products. So, we have been busy with this precious gift. In addition to making it available to the entire research community, we have already identified several promising “hit” compounds that show activity against hepatitis B.
HBF’s Baruch S. Blumberg Prize presented to Dr. Howard Koh

HBF presents the inaugural Baruch S. Blumberg Prize to Howard Koh, MD, MPH, Assistant Secretary for Health, U.S. Department of Health and Human Services, at the Crystal Ball.

“Einstein’s Table: The Search To Find A Cure for Chronic Hepatitis B” written by Kimberly Jungkind is the first publication that chronicles the Hepatitis B Foundation story and its mission.

Preventable Loss of My Brother

By John

A frantic call from my sister-in-law shattered our Labor Day weekend in 2010. My brother was in the ER for severe abdominal pain. We learned he had stage 4 inoperable liver cancer due to hepatitis B. We had no idea that he had chronic hepatitis B. He was a healthy 47-year old architect, avid skier, and father.

This was the beginning of the most heart-wrenching six months for our family. For me it was the most intense period of my life as I saw the older brother whom I loved and admired deteriorate so quickly. My brother passed away on March 6, 2011.

Naturally my thoughts went to how his death could have been prevented. The more I learned, the more anguished I became knowing that his death could have been prevented. As a result, I am committed to improving public awareness of this devastating disease. I share our family’s story with the hope that those at risk may be diagnosed earlier and benefit from treatment.

NEW DEDICATED LIVER CANCER PROGRAM

HBF launched www.LiverCancerConnect.org, the first patient-focused website that provides information and support to those facing the challenge of primary liver cancer.
Changing Practice and Policy

We are publishing articles in peer-reviewed journals that are helping to change clinical practice and national policy around hepatitis B.

- **Our screening algorithm and recommendations** for primary care providers have been published in prestigious medical journals for family doctors, internists, obstetricians, and nurse practitioners (an article for physician assistants is in the works).
- **Our public health research** has been highlighting the under-estimation and under-treatment of hepatitis B. The most recent publication questions whether treatment is needed for patients who fall outside of the current treatment guidelines since they are still at considerable risk for developing liver cancer.

CDC Updates Recommendations for HBV-Infected Healthcare Workers and Students

We have succeeded in working with the CDC to update its recommendations for HBV-infected healthcare workers and students based on our experience in assisting many young people facing discrimination because of their chronic hepatitis B infections. The CDC’s new recommendations clearly state that hepatitis B is not a condition that should preclude any infected person from pursuing a career or practice in healthcare.
Launch of Hep B United National Campaign

The HBF is proud to have been at the forefront of starting “Hep B United” in partnership with the Association for Asian Pacific Community Health Organizations. It is a national campaign comprised of more than 14 local coalitions from across the country, federal partners that include the CDC, U.S. Office of Minority Health, White House Initiative for Asian and Pacific Islanders, and the U.S. Department of Health and Human Services, and corporate partners including Gilead and GlaxoSmithKline. We hosted the first Hep B United National Summit at the HBF headquarters in Bucks County, PA.

Opportunity + International Programs

Gateway to Care Project in Haimen City, China

Our public health campaign in Haimen City has screened 12,000 adults, educated 1,200 primary care physicians, and tested all 5,700 women in the city who became pregnant during 2011-2012. We are referring infected adults to care and ensuring that babies born to infected moms receive the birth-dose hepatitis B vaccine and HBIG to protect them from a chronic infection.

Scientists Without Borders

Our “Scientists Without Borders” is an international research exchange program that currently includes agreements with three medical universities in mainland China. To date HBF has sponsored 6 international scientists for 2 to 3 year fellowships as part of this innovative program.
Our Donor Honor Roll
JULY 1, 2011 – JUNE 30, 2012

The Hepatitis B Foundation’s valuable research and programs is supported by generous individual donations, grants, workplace and matching gifts, in-kind donations, donations of auction items and sponsorships for our Crystal Ball, and attendance at our special events. We are grateful to every individual and organization that has stepped forward to advance our Cause for a Cure. Thank you!

Benefactor’s Society
($1,000 - $10,000 and more)

Visionary Circle
($10,000 and more)
Timothy & Joan Block
Gunst Charitable Foundation
Kahn Charitable Foundation
Univest National Bank

Global Circle
($5,000 - $9,999)
Fulton Bank
Kevin Kruse
Robert and Maria Lin Fund of The New York Community Trust
W. Robert Magee, Jr. & Paula Wong
Pamela Norton & Joseph Potz

Founders’ Circle
($2,500 - $4,900)
Anonymous
Callidus Biopharma
Bonnie Chang & Robert Hsu
Citrin Cooperman
Jan Findley
High Swartz LLP
Dmitriy Kachin
W. Thomas & Linda London

Patrons ($500 - $999)
Drexel University College Medicine
Mike Dugery
Dynavax Technologies
Eisner Amper
Enantion Therapeutics
Craig & Janet Estery
The Estery Family Fund of
The Pittsburgh Foundation
Fox Rothschild LLP
Matthew and Anne Greene
David & Jacqui Griffith
Joseph Hediger
Jenel & Cohen PC
Grace John
Ms. Amy Ko-Tang
Michael & Tomoko Malaghan
Medical Diagnostic Laboratories
Dr. and Mrs. Joseph Murphy
Penn Color, Inc.
Pharmabridge, Inc.
Jin Richmond
Joel & Nancy Rosen
Charles & Kit Sigety
Susan Stellini
Dexter Sun
Bud & Priscilla Tennant
Asian Pacific Association of
Medical Students (Jefferson U. and
U. Pennsylvania Chapters)
Tuichin Family Foundation
United Way of Southeastern PA
Brian Wigdahl & Betty Condran
Paul & Janine Witte

Presidents’ Circle
($1,000 - $2,499)
Victor Araya
Bank of America
United Way Campaign
Mary Boatner
Slan & Gerri Broadbent
Faith Calhoun
Elizabeth Chen
Gang Chen
Courtney Colletti
James & Susan Datin

In Appreciation + Gratitude
Benefactor’s Society
($1,000 - $10,000 and more)

[TO THE WONDERFUL PEOPLE AT THE HEPATITIS B FOUNDATION, I’VE ATTENDED THE “B” INFORMED PATIENT CONFERENCES AND BEEN SO IMPRESSED WITH YOUR WHOLE ORGANIZATION. I’VE LEARNED SO MUCH AND BEEN ENCOURAGED AS WELL. ... THANK YOU FOR THE WONDERFUL WORK YOU ALL DO!] – FAMILY FROM THE U.S. NORTH WEST
In Appreciation + Gratitude

Supporters ($100 - $249)
Muhammad Aamir
Michael Alfenfia
America's Charities
Susannah Amitye
Susan Bellaire
Earl & June Bierman
Sashi Binani
Joyce Block
Susan Braithwaite
M/M Ethan Byler
Haiman Cai
Pamela Cantrell-Self
Arthur Caputi
Jose Mari Casas
Ronald Chang
Charissa Chang
Garrett Chang
Leona Chen
Feng Chen
Terri Chen
P. (Peter) Chang
Christy Chiou
Hsinhuei Chiou
Suzanne Crilley
James & Carol Curry
Raymond D'Auria
M/M William Donaldson
Thomas Doyle
Marilyn Durbin
James Dzikowski
John Evans
James & Peggy Farley
Fiberline
Anthony & Jane Ford-Hutchinson
John Foss
Thomas Freeman
Lawrence Friedman
Eric & Elizabeth Friedman
Curt & Roseann Friehs
M/M Roger Gallic, Jr.
Paul Galvin
Marshall Garland
Sinnathamby Gomathinayagam
Joseph Gonnella
M/M Richard Haliburton
Richard & Hie-Won Hann
David Harper
Hiroko Hatanaka
Anne Heacook
Harry Hicks
M/M David Hines
Richard & Laura Holmes
Max Holt
David Huang
Infectious Awareables
Maureen Kamischke
Virginia Kamsky
Margaret Keenan
Kathleen Kerrigan
Dan Kilcup
Dale Kindregan
Albert Ku
Patrick Lam
M/M Michael Landis
Corina Larkin
Scott & Daryl Mackeverican

Friends (Up to $99)
Ishola Adeyemo
Mr. Matthew Adair-gail
Satabhish Aeka
Renee Agostino
JoAnne Albert
Pantelis Andriopoulos
Elsa Arsenault
Alexandre Baitine
Vicki Baker
Barisidaci
Priscilla Bizer
Geraldine Block
Michael Bolioth
M/M Stephen Borowski
Ronald Bradt
Daniel Brown
M/M Everett Chambers
Ko-Ming Chan
M/M Joseph Chan
Manju Chatani-Gada
Alice Cheung
Stephen Chow
David & Kathleen Christenson
Ignacio Chua
Henry Chuang
Jeffrey Civillico
William & Rita Clark
Marc & Ann Clearfield
Cheryl Clement
M/M Robert Cohen
Bertha Conyers
James & Joan Copp
Margaret Davey
R. Kimber & Christine David
M/M Paul Dominguex
Li Dong
Drexel Student Project Association
Vicki Shteiir Dunn
Northrop Grumman
Giga Edwards
Employee Charity Org Northrop Grumman
Asmar Eyvazova
Susan Felker
Brian Free
Anne Frey
Kathleen Garcia
Khamvilya Gebretensai
Genovecy Community Alliance
Andres Gentry
Thomas George
Gail Gershon
GoodSearch
William Green
Inge Green
Timothy Greene
Julie Hafner
Clare Hamilton-Hopkins
Sharon Hanson
M/M John Haun
Edwina Hawes
Hunt Hawkins
Betty Henderson
Thomas Herzer
M/M Peter Hoekstra

Hollenbach Family
Kenny Hom
Xiaolong Hong
Michael Horn
Evelyn Huang
Jun Iwata
Momodou Jobe
M/M Barry Kahn
Kantar Health
Nina Katz
Dorothy Kent
Jai Kim P.E.
Pandelis Kolomitro
Alex Koszyczki
KPMG Bergen County United Way
Debbie Kurkoski
Michel Lapointe
Karen Lassman-Eul
Mark Chengchun Lee
Rachel Lefkowitz
Edward Lincoln
M/M Michael Line
Ms. Rosie Ly
Marlene Madincea
Sarah Mannino
E. Mather
M/M Jim McGowan
Jennifer Mead
Jacqueline Medina
Karen Mera
Jack & Hannah Michelson
Nancy Miller
M/M John Miller, Jr.
Razvan Mircea
Edith Mock
Leslie Moore
Kathryn Moore
Motorola Mobility Foundation
Louis Muzekari
Judith Nelson
Meimei Ng
M/M John Oldani
Paulo Oliveria
Michael & Maryellen Ovitt
Joseph Paquilligan
Dominic Pasquarosa
William Peng
John Perez
Carl Peridier
Yuriy Petushkov
Aldersen Picar
Dzmitry Pravatorau
M/M Robert Radenbaugh
Susan Reeves
Carol Rico
Amy Sanderson
Fern Sanford
John Sherwin
I., Earl & Janet Nancy Simon
M/M Michael Sinn
Terry Spencer
Alexandranc Stancov
Major Harriet Stenzel
Lionne Stephens
Roger J Sun
M/M John Sweeney
M/M James Talamonti
In Appreciation + Gratitude

Friends (Up to $99) continued
Venkata Tallapanen
Wendy Tanaka
Janet Tangelney
Zeshan Taqueer
James Testa
M/M Harry C. Tse
Hin Wing Tse
Walter Tsou
United Way California Capital Region
United Way of Central NY
Ron Uroda
Carrie Welch
Endale Weldeyohannes
Vanessa Wenzel
Catherine Wolfe
Hazel Wong
David Woody
Ke-Chang Wu
Jin Xu
Feng Xu

Foundation and Corporate Grants
The Barra Foundation
Bristol-Myers Squibb
Bristol-Myers Squibb Foundation
Gilead Sciences
Hoffman-La Roche
Inovio Pharmaceuticals
Insight Pharmaceuticals
Edwin T. Johnson & Cynthia S. Johnson Foundation
Synergy Pharmaceuticals

Matching Gift Programs
Amgen Foundation Matching Gifts
AT&T United Way Employee Giving
ECHO Employees Charity Organization of Edison International
Give With Liberty Campaign
Glenmede Trust Company
IBM Employee Services Center
Johnson & Johnson Family Companies
Merck Partnership for Giving
E Microsoft Giving Campaign
Nvidia Employee Giving Program
The Prudential Foundation Matching Gifts
Shell Oil Co Found Matching Gifts
Wells Fargo Community Support Campaign

Federal and State Grants
Centers for Disease Control and Prevention
National Institutes of Health
PA Department of Health

We apologize for any errors or omissions in the donor list despite our best efforts to be as accurate as possible. Please contact editor@hepb.org or call 215-489-4900 so that we can print corrections in our next newsletter. Thank you.

In Appreciation + Gratitude

Friends (Up to $99) continued
Venkata Tallapanen
Wendy Tanaka
Janet Tangelney
Zeshan Taqueer
James Testa
M/M Harry C. Tse
Hin Wing Tse
Walter Tsou
United Way California Capital Region
United Way of Central NY
Ron Uroda
Carrie Welch
Endale Weldeyohannes
Vanessa Wenzel
Catherine Wolfe
Hazel Wong
David Woody
Ke-Chang Wu
Jin Xu
Feng Xu

Foundation and Corporate Grants
The Barra Foundation
Bristol-Myers Squibb
Bristol-Myers Squibb Foundation
Gilead Sciences
Hoffman-La Roche
Inovio Pharmaceuticals
Insight Pharmaceuticals
Edwin T. Johnson & Cynthia S. Johnson Foundation
Synergy Pharmaceuticals

Matching Gift Programs
Amgen Foundation Matching Gifts
AT&T United Way Employee Giving
ECHO Employees Charity Organization of Edison International
Give With Liberty Campaign
Glenmede Trust Company
IBM Employee Services Center
Johnson & Johnson Family Companies
Merck Partnership for Giving
E Microsoft Giving Campaign
Nvidia Employee Giving Program
The Prudential Foundation Matching Gifts
Shell Oil Co Found Matching Gifts
Wells Fargo Community Support Campaign

Federal and State Grants
Centers for Disease Control and Prevention
National Institutes of Health
PA Department of Health

We apologize for any errors or omissions in the donor list despite our best efforts to be as accurate as possible. Please contact editor@hepb.org or call 215-489-4900 so that we can print corrections in our next newsletter. Thank you.

In Appreciation + Gratitude

Friends (Up to $99) continued
Venkata Tallapanen
Wendy Tanaka
Janet Tangelney
Zeshan Taqueer
James Testa
M/M Harry C. Tse
Hin Wing Tse
Walter Tsou
United Way California Capital Region
United Way of Central NY
Ron Uroda
Carrie Welch
Endale Weldeyohannes
Vanessa Wenzel
Catherine Wolfe
Hazel Wong
David Woody
Ke-Chang Wu
Jin Xu
Feng Xu

Foundation and Corporate Grants
The Barra Foundation
Bristol-Myers Squibb
Bristol-Myers Squibb Foundation
Gilead Sciences
Hoffman-La Roche
Inovio Pharmaceuticals
Insight Pharmaceuticals
Edwin T. Johnson & Cynthia S. Johnson Foundation
Synergy Pharmaceuticals

Matching Gift Programs
Amgen Foundation Matching Gifts
AT&T United Way Employee Giving
ECHO Employees Charity Organization of Edison International
Give With Liberty Campaign
Glenmede Trust Company
IBM Employee Services Center
Johnson & Johnson Family Companies
Merck Partnership for Giving
E Microsoft Giving Campaign
Nvidia Employee Giving Program
The Prudential Foundation Matching Gifts
Shell Oil Co Found Matching Gifts
Wells Fargo Community Support Campaign

Federal and State Grants
Centers for Disease Control and Prevention
National Institutes of Health
PA Department of Health

We apologize for any errors or omissions in the donor list despite our best efforts to be as accurate as possible. Please contact editor@hepb.org or call 215-489-4900 so that we can print corrections in our next newsletter. Thank you.

In Appreciation + Gratitude

Friends (Up to $99) continued
Venkata Tallapanen
Wendy Tanaka
Janet Tangelney
Zeshan Taqueer
James Testa
M/M Harry C. Tse
Hin Wing Tse
Walter Tsou
United Way California Capital Region
United Way of Central NY
Ron Uroda
Carrie Welch
Endale Weldeyohannes
Vanessa Wenzel
Catherine Wolfe
Hazel Wong
David Woody
Ke-Chang Wu
Jin Xu
Feng Xu

Foundation and Corporate Grants
The Barra Foundation
Bristol-Myers Squibb
Bristol-Myers Squibb Foundation
Gilead Sciences
Hoffman-La Roche
Inovio Pharmaceuticals
Insight Pharmaceuticals
Edwin T. Johnson & Cynthia S. Johnson Foundation
Synergy Pharmaceuticals

Matching Gift Programs
Amgen Foundation Matching Gifts
AT&T United Way Employee Giving
ECHO Employees Charity Organization of Edison International
Give With Liberty Campaign
Glenmede Trust Company
IBM Employee Services Center
Johnson & Johnson Family Companies
Merck Partnership for Giving
E Microsoft Giving Campaign
Nvidia Employee Giving Program
The Prudential Foundation Matching Gifts
Shell Oil Co Found Matching Gifts
Wells Fargo Community Support Campaign

Federal and State Grants
Centers for Disease Control and Prevention
National Institutes of Health
PA Department of Health

We apologize for any errors or omissions in the donor list despite our best efforts to be as accurate as possible. Please contact editor@hepb.org or call 215-489-4900 so that we can print corrections in our next newsletter. Thank you.

In Appreciation + Gratitude

Friends (Up to $99) continued
Venkata Tallapanen
Wendy Tanaka
Janet Tangelney
Zeshan Taqueer
James Testa
M/M Harry C. Tse
Hin Wing Tse
Walter Tsou
United Way California Capital Region
United Way of Central NY
Ron Uroda
Carrie Welch
Endale Weldeyohannes
Vanessa Wenzel
Catherine Wolfe
Hazel Wong
David Woody
Ke-Chang Wu
Jin Xu
Feng Xu

Foundation and Corporate Grants
The Barra Foundation
Bristol-Myers Squibb
Bristol-Myers Squibb Foundation
Gilead Sciences
Hoffman-La Roche
Inovio Pharmaceuticals
Insight Pharmaceuticals
Edwin T. Johnson & Cynthia S. Johnson Foundation
Synergy Pharmaceuticals

Matching Gift Programs
Amgen Foundation Matching Gifts
AT&T United Way Employee Giving
ECHO Employees Charity Organization of Edison International
Give With Liberty Campaign
Glenmede Trust Company
IBM Employee Services Center
Johnson & Johnson Family Companies
Merck Partnership for Giving
E Microsoft Giving Campaign
Nvidia Employee Giving Program
The Prudential Foundation Matching Gifts
Shell Oil Co Found Matching Gifts
Wells Fargo Community Support Campaign

Federal and State Grants
Centers for Disease Control and Prevention
National Institutes of Health
PA Department of Health

We apologize for any errors or omissions in the donor list despite our best efforts to be as accurate as possible. Please contact editor@hepb.org or call 215-489-4900 so that we can print corrections in our next newsletter. Thank you.
Year In Review + Financial Information

For the fiscal year ended June 30, 2012

Sources of Funds
HBF & IHVR Combined
(Total $4,799,443)

- Grants 75% ($3,622,748)
- Charitable Contributions 16% ($776,259)
- Natural Products Revenue 3% ($125,997)
- Management Fees 3% ($130,000)
- Special Events 2% ($72,803)
- Other Revenue 1% ($71,636)

Uses of Funds
HBF & IHVR Combined
(Total $4,524,927)

- Direct Research 49% ($2,199,855)
- Natural Products Institute 10% ($447,295)
- Outreach and Education 17% ($773,818)
- Public Health 7% ($305,313)
- Biotechnology Programs 2% ($110,047)
- General and Administrative 14% ($614,269)
- Development 2% ($73,330)

[ Our daughter was adopted from China and most likely infected at birth. She is now ten (very healthy!). Your work to increase awareness of Hepatitis B will surely lead to more extensive research, and—I pray—an eventual cure. Thank you. ] — Grateful mom

The financial information presented above does not include the activity from Hepatitis B Foundation’s 50% interest in the net assets of the Pennsylvania Biotechnology Center. On June 30, 2012, this interest was valued at approximately $3.18 million per the audited Statement of Financial Position of the Hepatitis B Foundation. The Pennsylvania Biotechnology Center was founded by the HBF in 2006, in partnership with a local college.

*The financial information in this report was prepared by management and presented in condensed form from the financial statements of the Hepatitis B Foundation and the Institute for Hepatitis Research audited by EisnerAmper, LLP for the year ended June 30, 2012. A copy of each financial statement is available upon request.
Learn more about hepatitis B and the important work of the Hepatitis B Foundation by visiting www.hepb.org.

3805 Old Easton Road, Doylestown, PA 18902
Phone: (215) 489-4900  Fax: (215) 489-4920
Email: info@hepb.org

Join Our Global Conversation